Tech Company Financing Transactions
Aureon Biosciences Funding Round
Accomplice, Pfizer Venture Investments and Sprout Group participated in a $20 million Series B funding round for Aureon Biosciences. The funding round was announced on 8/3/2005.
Transaction Overview
Company Name
Announced On
8/3/2005
Transaction Type
Venture Equity
Amount
$20,000,000
Round
Series B
Proceeds Purpose
With our Series B funding secured, Aureon will move aggressively toward concluding its clinical validation work and prepare for the commercial launch of its initial Prostate Px.
Company Information
Company Status
Out of Business
Industry
Medical Devices & Instruments
Mailing Address
28 Wells Ave.
Yonkers, NY 10701
USA
Yonkers, NY 10701
USA
Phone
Website
Email Address
Overview
Aureon Biosciences is a life science company founded in 2002, dedicated to enabling the advancement of predictive and personalized cancer treatment options.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Robert Shovlin
Chief Financial Officer
Robert Nostrand
Chief Scientific Officer
Michael Donovan
VP - Finance
Michael Facendola
VP - Marketing
Jason Alter
VP - Operations
Charles DiComo
VP - Sales
David Brown
Browse more venture capital transactions:
Prev: 8/2/2005: Visiprise venture capital transaction
Next: 8/4/2005: SemEquip venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs